Literature DB >> 12746322

Osteonectin-null mutation compromises osteoblast formation, maturation, and survival.

Anne M Delany1, Ivo Kalajzic, Amy D Bradshaw, E Helene Sage, Ernesto Canalis.   

Abstract

Osteonectin, also known as SPARC (secreted protein acidic and rich in cysteine) or BM-40, is one of the most abundant noncollagenous proteins in bone. Analysis of osteonectin-null mice revealed that osteonectin is necessary for the maintenance of bone mass and normal remodeling, as osteonectin-null mice have decreased osteoblast number and bone formation rate. Cultures of bone marrow stromal cells and osteoblasts from control and osteonectin-null mice were used to determine the cellular basis for the mutant phenotype. We found that marrow stroma from osteonectin-null mice contains fewer osteoblastic precursors than that of control mice, and the osteonectin-null mutation did not affect the proliferation rate of stromal cells or osteoblasts. Whereas osteonectin-null cells could adopt an osteoblastic phenotype, a smaller proportion of these cells expressed markers of a fully differentiated osteoblast. Mutant cells exhibited decreased formation of mineralized nodules, as well as diminished expression of osteocalcin mRNA and response to PTH. Furthermore, osteonectin-null cells showed an increased tendency to form adipocytes, with enhanced expression of the adipocytic markers adipsin and CCAAT/enhancer binding protein delta. Osteonectin-null cells were also more susceptible to environmental stresses. These data indicate that osteonectin is important for osteoblast formation, maturation, and survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746322     DOI: 10.1210/en.2002-221044

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  54 in total

1.  Extracellular microfibrils control osteoblast-supported osteoclastogenesis by restricting TGF{beta} stimulation of RANKL production.

Authors:  Harikiran Nistala; Sui Lee-Arteaga; Silvia Smaldone; Gabriella Siciliano; Francesco Ramirez
Journal:  J Biol Chem       Date:  2010-08-21       Impact factor: 5.157

Review 2.  MicroRNA variants as genetic determinants of bone mass.

Authors:  Neha S Dole; Anne M Delany
Journal:  Bone       Date:  2015-12-23       Impact factor: 4.398

3.  Laminin-5 activates extracellular matrix production and osteogenic gene focusing in human mesenchymal stem cells.

Authors:  Robert F Klees; Roman M Salasznyk; Scott Vandenberg; Kristin Bennett; George E Plopper
Journal:  Matrix Biol       Date:  2006-10-13       Impact factor: 11.583

Review 4.  Bone biology: insights from osteogenesis imperfecta and related rare fragility syndromes.

Authors:  Roberta Besio; Chi-Wing Chow; Francesca Tonelli; Joan C Marini; Antonella Forlino
Journal:  FEBS J       Date:  2019-07-05       Impact factor: 5.542

5.  Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.

Authors:  Rodrigo D A M Alves; Marco Eijken; Karel Bezstarosti; Jeroen A A Demmers; Johannes P T M van Leeuwen
Journal:  Mol Cell Proteomics       Date:  2013-06-17       Impact factor: 5.911

6.  Mapping of SPARC/BM-40/osteonectin-binding sites on fibrillar collagens.

Authors:  Camilla Giudici; Nicolas Raynal; Hanna Wiedemann; Wayne A Cabral; Joan C Marini; Rupert Timpl; Hans Peter Bächinger; Richard W Farndale; Takako Sasaki; Ruggero Tenni
Journal:  J Biol Chem       Date:  2008-05-16       Impact factor: 5.157

7.  miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling.

Authors:  Kristina Kapinas; Catherine B Kessler; Anne M Delany
Journal:  J Cell Biochem       Date:  2009-09-01       Impact factor: 4.429

8.  A single nucleotide polymorphism in osteonectin 3' untranslated region regulates bone volume and is targeted by miR-433.

Authors:  Neha S Dole; Kristina Kapinas; Catherine B Kessler; Siu-Pok Yee; Douglas J Adams; Renata C Pereira; Anne M Delany
Journal:  J Bone Miner Res       Date:  2015-04       Impact factor: 6.741

9.  Osteopenia in Sparc (osteonectin)-deficient mice: characterization of phenotypic determinants of femoral strength and changes in gene expression.

Authors:  Fiona C Mansergh; Timothy Wells; Carole Elford; Samuel L Evans; Mark J Perry; Martin J Evans; Bronwen A J Evans
Journal:  Physiol Genomics       Date:  2007-09-18       Impact factor: 3.107

10.  SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling.

Authors:  Jing Nie; E Helene Sage
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.